[
    {
        "type": "text",
        "text": "临床研究",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "广东地区冠心病患者外周血中eHSP90α的表达水平及意义",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "吕自明,蔡 凯,李巧汶,李健洪广州医科大学附属第六医院胸心五区，广东清远511518摘要：目的 探讨eHSP90α在冠心病发生发展中的作用和意义。方法 选取2013年6月 ${ \\sim } 2 0 1 6$ 年6月在本院住院的广东籍冠心病患者101例及对照组31例，收集病情资料，检测外周血eHSP90α含量。分析外周血eHSP90α含量与冠心病患者病情的关系。结果冠心病患者外周血中eHSP90α水平较对照组升高 $\\scriptstyle ( P < 0 . 0 1 )$ 。不稳定型冠心病患者外周血eHSP90α含量高于稳定性冠心病患者 $( 9 2 . 1 7 { \\scriptstyle \\pm 2 3 . 6 3 ~ \\mathrm { n g / L } }$ vs $1 5 . 8 4 { \\pm } 1 5 . 8 3 ~ \\mathrm { n g / L } , P { < } 0 . 0 1 )$ ，冠心病合并心衰患者外周血eHSP90α含量高于不合并心衰发生的患者 $( 9 3 . 0 4 { \\pm } 2 2 . 9 4 ~ \\mathrm { n g / L }$ vs $8 1 . 4 9 { \\pm } 2 0 . 4 4 ~ \\mathrm { n g / L } , P { < } 0 . 0 5 )$ 。冠心病合并IV级、II级心衰患者外周血 $\\mathrm { e H S P 9 0 a }$ 差异没有统计学意义$\\scriptstyle \\left( P = 0 . 1 5 8 \\right)$ 。结论血中 $\\mathrm { e H S P 9 0 a }$ 含量与广东地区冠心病患者病情相关，进一步深入研究也许可作为冠心病病情血学标志。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：冠心病； $\\mathrm { e H S P 9 0 a }$ ；心衰 ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Expression and significance of eHSP9Oα in peripheral blood of patients with coronary hearl disease in Guangdong ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "LV Ziming, CAI Kai, LI Qiaowen,LI Jianhong   \nTheFifthDistrictineprtmentofoacicdCardooasularurgerytheithfliatedHospitalofGuangzouMedicalsity   \nQingyuan 511518,China ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Abstract: Objective To investigate the effect of secreted $\\mathrm { H s p } 9 0 \\alpha$ (eHSP90α) on the development and progression of coronary heart disease (CHD).Methods A totalof 101 patients withCHDand31 casesas healthycontrol group were enroled in this study from June 2013 to June 2016.TheeHSP90αlevels in peripheralbloodofall cases werecolected.Thecorrelationof $\\mathrm { e H S P 9 0 } \\alpha$ levels in peripheral blood with condition of patients with CHD was analyzed.Results The eHSP90α levels in peripheral blood of patients with CHD was significantly higher than that of healthy control group $( P { < } 0 . 0 1 )$ . In patients with CHD, $\\mathrm { e H S P 9 0 } \\alpha$ levels in peripheral blood in unstable CHD group was significantly higher than that in stable CHD group $( P { < } 0 . 0 1 )$ .The eHSP90α levels in peripheral blood in CHD combined with heart failure was significantly higher than that in patients group without heart failure $_ { ( P < 0 . 0 5 ) }$ . The eHSP90α levels in peripheral blood of CHD patients with grade $\\mathrm { \\Delta W }$ heart failure had no significant difference with grade II heart failure patients $_ { ( P = 0 . 1 5 8 ) }$ . Conclusion The $\\mathrm { e H S P 9 0 } \\alpha$ levels in peripheral bloodarecloselyrelated totheconditionofCHDin Guangdong.Itmaybeaserological markerofcoronaryheart disease by further study. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Keyword: coronary heart disease; eHSP9Oα; heart failure ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "冠心病是在冠状动脉粥样硬化病理基础上，因多种危险因素诱发的动脉粥样斑块破裂和血栓形成，造成管腔狭窄甚至闭塞，进而心肌缺血，严重引起心肌梗死的病理生理过程[-2]。在这一过程中，心肌细胞损伤可引起细胞内大量物质分泌，如肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白(cTnI)等都大量增加，已成为冠心病诊断的血清指标[3-4]。热休克蛋白90(HSP90)是一类高度保守的蛋白质，约占胞质蛋白的 $1 \\% { \\sim } 2 \\%$ ，有 $\\mathfrak { a }$ 和β两种亚型[5]。近年来,外周血中分泌型 $\\mathrm { H s p 9 0 a ( e H S P 9 0 a ) }$ 日愈受到关注，被证明与肿瘤、炎症、细胞损伤等有密切关系[67]。但是,eHSP90α与冠心病的发病及严重程度之间的关系鲜有报道。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "因此，本研究将通过研究广东地区冠心病患者外周血中eHSP90α表达水平，初步探索eHSP90α在冠心病发病中的关系和临床意义。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1资料与方法",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1.1一般资料",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "选自2013年6月\\~2016年6月，我院诊断为冠心病的广东籍患者101例，其中男性64例，女性37例；稳定性心绞痛(SAP)51例，不稳定型心绞痛(ACS)50例(表1);按冠脉病变分型，A型35例，B1型30例，B2型21例，C型15例;按冠脉病变支数，一支冠脉病变43例，两支冠脉病变36例，三支冠脉病变22例。收集体检中心健康对照组31例，无重要脏器病变和恶性疾病。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "病例排除标准：严重高血压患者；创伤或4周内行手术者；各类肿瘤；非动脉粥样硬化性心肌病；严重心瓣膜病；心肌肥厚；系统性红斑狼疮、类风湿性关节炎、系统性硬化症等自身免疫性疾病；肺纤维化；各种急慢性感染性疾病。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/288700f6532f8995035ef82c04e156fb0abba3f5a8a77ff87b1c167e0a8f0de9.jpg",
        "table_caption": [
            "表1稳定型和不稳定型冠心病患者基本情况和血eHSP90α含量"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>组别</td><td>n</td><td>男/女</td><td>年龄(岁)</td><td>eHSP90α (ng/L)</td></tr><tr><td>健康对照组</td><td>31</td><td>10/21</td><td>69.12±13.12</td><td>63.95±22.50</td></tr><tr><td>稳定型</td><td>51</td><td>34/17</td><td>67.95±10.74</td><td>15.84±15.83</td></tr><tr><td>不稳定型</td><td>50</td><td>30/20</td><td>71.29±9.25</td><td>92.17±23.63</td></tr><tr><td>P</td><td></td><td>0.711</td><td>0.306</td><td>0.00</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2研究方法",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2.1外周血中eHSP90α含量检测患者入院后采集静脉血 $5 ~ \\mathrm { m L }$ ， $^ { 2 \\mathrm { ~ h ~ } }$ 内离心 $( 3 0 0 0 \\ \\mathrm { r / m i n } , 4 \\ \\mathrm { \\textcircled { C } ) 1 5 \\ \\mathrm { m i n } }$ 取血约 $1 . 5 ~ \\mathrm { m L }$ ，分装后 $- 8 0 \\mathrm { ~ \\textdegree C }$ 冰箱冻存。待标本收集齐全后进行统一检测。采用ELISA法检测 $\\mathrm { e H S P 9 0 a }$ (CloudClone，USA)，680全自动酶标仪检测(BIO-RAD,USA)。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2.2统计学处理用SPSS19.0统计学软件进行数据的统计学处理，计量资料以均数 $\\cdot \\pm \\cdot$ 标准差表示。多组计量数据比较采用多个独立样本非参数检验，各组间数据比较使用单因素方差分析，两组间连续变量比较使用t检验，组内两两比较采用SNK法。以$P { < } 0 . 0 5$ 为差异有统计学意义。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2结果",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.1稳定型和不稳定型冠心病患者基本情况和血 eHSP90α含量的差异 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "健康对照组，稳定型和不稳定型冠心病患者在性别和年龄分布上没有显著差异。稳定型和不稳定型冠心病患者血 $\\mathrm { \\ e H S P 9 0 a }$ 含量较健康对照组明显增高，差异有统计学意义；同时，不稳定型组血eHSP90α也较稳定型组显著增高 $( P { < } 0 . 0 1$ ，表1)。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.2不同冠脉病变分型冠心病患者基本情况和血eHSP90α含量的差异",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "健康对照组、A组、B1组、B2组和C组在在性别和年龄分布上没有显著差异。A组、B1组、B2组和C组血eHSP90α含量较健康对照组显著增高;B1组和A组、B2组间血 $\\mathrm { e H S P 9 0 a }$ 含量没有显著差异，B2组和C组间血e $\\operatorname { \\cdot H S P 9 0 a }$ 含量没有显著差异，而B2组血$\\mathrm { e H S P 9 0 a }$ 含量较A组显著升高，C组血eHSP $9 0 \\alpha$ 含量较B1组和A组显著升高 $( P { < } 0 . 0 1$ ，表2)。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.3不同冠脉病变支数冠心病患者基本情况和血eHSP90α含量的差异",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "不同冠脉病变支数冠心病患者在性别和年龄分布上没有显著差异。两支冠脉病变和三支冠脉病变",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "血eHSP90α含量较一支冠脉病变显著增高；三支冠脉病变较两支冠脉病变血eHSP90α含量有所升高，但无显著差异(表3)。",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/0c18ff8b6dc3ef3f62611f051660658b7e1af6dfef80cd798cdbcab395b17976.jpg",
        "table_caption": [
            "表2不同冠脉病变分型冠心病患者基本情况和血eHSP90α含量"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>组别</td><td>n</td><td>男/女</td><td>年龄(岁)</td><td>eHSP90α (ng/L)</td></tr><tr><td>健康对照组</td><td>31</td><td>10/21</td><td>69.22±13.12</td><td>63.95±22.50</td></tr><tr><td>A组</td><td>35</td><td>20/15</td><td>70.36±10.12</td><td>75.92±19.06</td></tr><tr><td>B1组</td><td>30</td><td>10/20</td><td>67.22±10.61</td><td>83.07±16.10</td></tr><tr><td>B2组</td><td>21</td><td>7/14</td><td>72.23±7.73</td><td>88.52±20.95</td></tr><tr><td>C组</td><td>15</td><td>10/5</td><td>69.43±11.36</td><td>99.31±28.85</td></tr><tr><td>P</td><td></td><td>0.895</td><td>0.704</td><td>0.00</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/3d20b2a0a6206d0cd53166347e69ccb900c29841181f3393d915003838c40b0d.jpg",
        "table_caption": [
            "表3不同冠脉病变支数冠心病患者基本情况和血eHSP90α含量"
        ],
        "table_footnote": [
            "$^ * P { < } 0 . 0 5$ vs SV; $^ { * * } P { < } 0 . 0 1$ vs MV; $^ { \\triangle } P { < } 0 . 0 1$ vs对照组. "
        ],
        "table_body": "<html><body><table><tr><td>组别</td><td>n</td><td>男/女</td><td>年龄(岁)</td><td>eHSP90α (ng/L)</td></tr><tr><td>健康对照组</td><td>31</td><td>10/21</td><td>69.22±13.12</td><td>63.95±3.32</td></tr><tr><td>一支冠脉病变</td><td>43</td><td>30/13</td><td>68.08±11.42</td><td>76.15±15.89**△</td></tr><tr><td>两支冠脉病变</td><td>36</td><td>22/14</td><td>70.31±9.04</td><td>86.47±20.21*△</td></tr><tr><td>三支冠脉病变</td><td>22</td><td>12/10</td><td>71.16±9.28</td><td>93.51±27.50</td></tr><tr><td>P</td><td></td><td>0.619</td><td>0.283</td><td>0.00</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.4合并心衰和不合并心衰的冠心病患者血eHSP90α 含量的差异 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "心衰是冠心病患者的一类严重并发症。因此，通过对比冠心病合并心衰和冠心病不合并心衰患者血eHSP90α含量的差异，发现合并心衰的冠心病患者血 $\\mathrm { e H S P 9 0 a }$ 含量 $( 9 3 . 0 4 \\pm 2 2 . 9 4 ~ \\mathrm { n g / L } )$ 较不合并心衰的冠心病患者血 $\\mathrm { e H S P 9 0 a }$ 含量 $\\mathrm { ( 8 1 . 4 9 { \\pm } 2 0 . 4 4 ~ n g / L ) }$ 明显增高，差异有统计学意义 $\\scriptstyle { \\overbrace { P { = } 0 . 0 4 1 } }$ ,表4)。",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/f7db5b5b8baaa2a8750c5f1ff8886135a4b4bca27a016fa2d1a65f6fda215909.jpg",
        "table_caption": [
            "表4合并心衰和不合并心衰的冠心病患者血eHSP90α含量"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>组别</td><td>n</td><td>男/女</td><td>年龄(岁)</td><td>eHSP90a (ng/L)</td></tr><tr><td>冠心病不合并心衰患者</td><td>79</td><td>52/27</td><td>69.56±10.88</td><td>81.49±20.44</td></tr><tr><td>冠心病合并心衰</td><td>22</td><td>11/11</td><td>70.23±80.80</td><td>93.04±22.94</td></tr><tr><td>P</td><td></td><td>0.063</td><td>0.791</td><td>0.041</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.5不同心功能级别的冠心病合并心衰患者血eHSP90α含量的差异",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "本研究进一步对比了不同心功能级别的冠心病合并心衰患者血 $\\mathsf { e H S P 9 0 a }$ 含量的差异，结果显示，II级血 ${ \\tt s H S P 9 0 a }$ 含量 $( 8 7 . 3 3 { \\pm } 2 3 . 3 6 ~ \\mathrm { n g / L } )$ 较IV级血$\\mathrm { e H S P 9 0 a }$ 含量 $( 1 0 1 . 2 9 { \\pm } 2 0 . 8 1 ~ \\mathrm { n g / L } )$ )低，但差异没有统计学意义 ${ ( P \\mathrm { = } 0 . 1 5 8 }$ ，表5)。",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/900368c4fe78c3a1489847ac6442ec8ca42cbfe88f6300067fc10b444288f073.jpg",
        "table_caption": [
            "表5不同心功能级别的冠心病合并心衰患者血eHSP90α含量"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>组别</td><td>n</td><td>男/女</td><td>年龄</td><td>eHSP90α (ng/L)</td></tr><tr><td>IⅢI</td><td>13</td><td>7/6</td><td>67.85±9.53</td><td>87.33±23.36</td></tr><tr><td>IV</td><td>9</td><td>4/5</td><td>73.67±6.89</td><td>101.29±20.81</td></tr><tr><td>P</td><td></td><td>0.453</td><td>0.211</td><td>0.158</td></tr></table></body></html>",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "3讨论",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "Hsp90是重要的应激性蛋白之一，能在应激反应时迅速合成并激活，主要的作用是调节蛋白质聚集、折叠、跨膜、运输和转位，发挥稳定细胞骨架和作为分子伴侣等作用，是细胞抵抗早期应激性损伤的主要方式之—[8-9]",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "既往的研究发现，细胞内的HSP90可以通过调控eNOS参与NO合成来减少冠心病的发生发展[、调节PI3K-AKT信号通路减少细胞凋亡[]。在冠心病研究中发现患者血中总HSP90的水平较对照组明显升高,被认为是心血管的自我保护机制[12-13]。也有研究表明，应激原的作用下HSP90可以“主动\"分泌到细胞外或者应激导致的坏死细胞释放崩解后释放到细胞外(即eHSP90),可与TGF- ${ \\bf \\beta } \\cdot { \\bf \\{ \\beta \\} } $ 的受体结合促进心肌纤维化发生发展[14]",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "那么，eHSP90在冠心病中的作用如何?新近的研究发现，HSP90两个亚型中，分泌到细胞外的eHSP90α是其发挥作用的主要形式[。我们的结果发现冠心病患者血中HSP90的亚型eHSP90a的表达水平也较健康对照组显著升高。不稳定型冠心病患者血eHSP90a明显高于稳定性冠心病患者，冠脉血管病变多的也多于单一血管病变患者。我们一步的分析也发现，如果冠心病患者合并心衰发生，其血eHSP90α的表达水平高于不合并心衰发生的患者；并且心衰等级越高，eHSP90α的表达水平也越高，只是两者间差异不太显著，考虑病例数不足。可见，eHSP90a的表达水平与冠心病患者病情的严重程度密切相关。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "但是，冠心病患者血高水平的eHSP90α是否参与冠心病的发生发展呢?在其他的研究中发现,eHSP90α可以促进肿瘤细胞的增殖和转移[15-17]、增加成纤维细胞合成细胞外基质参与组织重构[14,18]、诱导炎症因子的生成参与炎症反应[19-20]等。因此，我们考虑心血管中内皮细胞、心肌细胞等中高 $\\mathrm { H s p 9 0 a }$ 在应激早期参与了心血管细胞的保护。但是分泌到细胞外的eHSP90α可能启动了炎症反应和心肌构成，促进了冠心病的发生发展。因此，下一步研究中，我们将在实验中进一步探讨eHSP90α对冠脉血管的作用,并研究其中的机制。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "综上所述，Hsp90作为体内重要的应激蛋白之一，在冠心病缺血缺氧的应激环境中发挥重要作用。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "eHSP90a其与冠心病患者病情的严重程度密切相关，可能可以作为冠心病患者病情变化及预后的血清学你。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "参考文献：   \n[1]Hashmi S,Ahmad HR,Sharif H,et al.Diastolic dysfunction in coronary artery disease[J].J Coll Physicians Surg Pak，2017, 27(3): 192.   \n[2]Senior R，Khattr RS. Cardiac investigation for prognosis in coronary artery disease: where negative is positive[J].Eur Heart J Cardiovasc Imaging,2017,25(8): 25.   \n[3]Fan J,Ma J, Xia N,et al. Clinical value of combined detection of CK-MB,MYO,cTnI and plasma NT-proBNP in diagnosis of acute myocardial infarction[J]. Clin Lab,2017,63(3): 427-33.   \n[4] Moludi J, Keshavarz S, Tabaee AS,et al. Q1O supplementation effects on cardiac enzyme CK-MB and troponin in patients undergoing coronary artery bypass graft:a randomized,doubleblinded,placebo-controlled clinical trial[J].JCardio Thorac Res, 2016, 8(1): 1-7.   \n[5]Walter R,Pan KT,Doebele C,et al.HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling[J].Bl0od,2017,129(5): 598-608.   \n[6] Zou M,Bhatia A,Dong H,et al.Evolutionarilyconserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression[J]. Oncogene,2017,36(15): 2160-71.   \n[7]Bhatia A, O'brien K,Chen M, et al. Keratinocyte-Secreted heat shock protein-9oalpha:leading wound reepithelialization and closure[J].Advances Wound Care,2016,5(4): 176-84.   \n[8] Blair LJ，Sabbagh JJ,Dickey CA.Targeting Hsp90 and its cochaperones to treat Alzheimer's disease[J]．Expert Opin Ther Targets,2014,18(10): 1219-32.   \n[9] Calderwood SK, Gong J. Heat shock proteins promote cancer: i's a protection racket[J].Trends Biochem Sci,2016,41(4): 311-23.   \n[10] Vladic N,Ge ZD,Leucker T,et al.Decreased tetrahydrobiopterin and disrupted association of Hsp90 with eNOS by hyperglycemia impair myocardial ischemic preconditioning[J]．Am J Physiol Heart Circ Physiol,2011,301(5): H2130-9.   \n[11]Gao ZM,LiuFH,YinP,etal.Inhibitionof heat-iducedapoposis in rat small intestine and IEC-6 cells through the AKT signaling pathway[J].BMC Vet Res,2013,9(8): 241.   \n[12]朱惠民，曾高峰．冠心病患者血清热休克蛋白90水平变化及意 义[J].实用医学杂志,2009,(04):576-7.   \n[13]刘代华，黄红林，廖端芳．热休克蛋白90在心血管系统中的作 用[J].国外医学:生理,病理科学与临床分册,2004,(05):473-5.   \n[14]Garcia R,Merino D,Gómez JM, et al.Extracellular heat shock protei 90 binding to TGFβ receptor I participates in TGFβ- mediated collagen production in myocardial fibroblasts [J].Cell Signal,2016,28(10): 1563-79.   \n[15]Hance MW,Dole K,Gopal U,et al.Secreted Hsp9O is a novel regulator of the epithelial to mesenchymal transition (EMT） in prostate cancer[J].JBiol Chem,2012,287(45): 37732-44.   \n[16]Nolan KD,Franco OE,Hance MW,et al. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion[J].JBiol Chem,2015,290(13): 8271-82.   \n[17]Dong H, Zou M,Bhatia A,et al. Breast Cancer MDA-MB-231 cells use secreted heat shock protein-9Oalpha (Hsp9Oα） to survive a hostile hypoxic environment[J].Sci Rep,2016,6(4): 20605.   \n[18]Bohonowych JE,Hance MW,Nolan KD,etal.ExtracellularHsp90 mediates an NF-kB dependent inflammatory stromal program: implications for the prostate tumor microenvironment[J].Prostate, 2014,74(4): 395-407.   \n[19]Tukaj S,Wegrzyn G.Anti-Hsp90 therapy in autoimmune and inflammatory diseases:a review of preclinical studies[J].Cell Stress Chaperones,2016,21(2):213-8.   \n[20]Ocana GJ,Pérez L,Guindon L，et al. Inflammatory stress of pancreatic beta cells drives release of extracellular heat-shock protein $9 0 \\alpha$ [J].Immunology,2017,151(2):198-210. ",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "(上接第314页)",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "[17]Canbolat AA,Timur C,Kalaycik O.A retrospective analysis of complications observed in children with acute lymphoblastic leukemia during chemotherapy[J].Minerva Pediatr,2017,69(2):95-105.   \n[18] Zhang BH,Wang J,Xue HM,et al.Impact of chemotherapy-related hyperglycemia on prognosis of child acute lymphocytic leukemia[J].Asian Pac JCancer Prev,2014,15(20):8855-9.   \n[19]Feltbower RG,Mckinney PA,Greaves MF,et al.International paralles inleukemia and diabetes epidemiology[J].Arch Dis Child, 2004,89(1): 54-6.   \n[20]沈志祥，周励.复发难治性淋巴瘤的治疗进展[J]．临床内科杂 志,2005,22(9): 580-2.   \n[21]Dare JM,Moppet JP,Shield JP,et al. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL)[J]．Pediatr Blood Cancer, 2013,60(12):E157-9.   \n[22]Khabori M,Minden MD,Yee KW,et al. Improved survival using anintensive,pediatric-based chemotherapyregimen in adultswith T-cell acute lymphoblastic leukemia[J].Leuk Lymphoma,2010, 51(1): 61-5.   \n[23]秦晓铧,陈 立,陈国枢,等.Hyper-CVAD方案治疗成人急性淋巴 细胞白血病疗效分析[J].中国医药科学,2011,22(6):65-7.   \n[24]潘 慈，汤静燕，薛惠良，等.急性淋巴细胞白血病患儿左旋门冬 酰胺酶联合化疗期间血糖监测的临床研究[J]．临床儿科杂志, 2012,30(5):415-6.   \n[25]刘 蒙,杨明珍,夏瑞祥,等.改良Hyper-CVAD/MA方案治疗25例 淋巴系统恶性肿瘤的临床分析[J]．中国肿瘤临床，2012，31(3): 166-9. ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    }
]